6 days Ago By ABMN Staff
Alliancebernstein L.P. lifted its stake in shares of Biohaven Ltd.
( NYSE:BHVN – Free Report ) by 6.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 96,236 shares of the company’s stock after acquiring an additional 5,951 shares during the quarter.
Alliancebernstein L.P.’s holdings in Biohaven were worth $3,594,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Spire Wealth Management bought a new position in Biohaven during the 4th quarter valued at $56,000. Amalgamated Bank lifted its holdings in shares of Biohaven by 21.
9% in the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock valued at $109,000 after buying an additional 527 shares during the period. US Bancorp DE lifted its holdings in shares of Biohaven by 36.
7% in the fourth quarter. US Bancorp DE now owns 2,971 shares of the company’s stock valued at $111,000 after buying an additional 798 shares during the period. KBC Group NV boosted its stake in Biohaven by 50.
1% during the fourth quarter. KBC Group NV now owns 3,377 shares of the company’s stock valued at $126,000 after buying an additional 1,127 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in Biohaven during the third quarter worth about $246,000.
Institutional investors own 88.78% of the company’s stock. Biohaven Trading Up 4.
7 % Shares of BHVN stock opened at $18.45 on Tuesday. The company has a market capitalization of $1.
88 billion, a price-to-earnings ratio of -1.97 and a beta of 1.33.
Biohaven Ltd. has a 1-year low of $15.79 and a 1-year high of $55.
70. The stock’s fifty day simple moving average is $30.03 and its 200-day simple moving average is $39.
27. Insider Buying and Selling In other news, Director John W. Childs acquired 32,700 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th.
The stock was acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00.
Following the completion of the acquisition, the director now owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. The trade was a 1.
43 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . 16.
00% of the stock is currently owned by corporate insiders. Wall Street Analysts Forecast Growth A number of brokerages have weighed in on BHVN. JPMorgan Chase & Co.
cut their price target on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th.
Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. HC Wainwright restated a “buy” rating and set a $54.00 target price on shares of Biohaven in a report on Tuesday, March 4th.
Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Finally, Deutsche Bank Aktiengesellschaft set a $60.
00 price objective on Biohaven and gave the stock a “buy” rating in a research note on Thursday, March 20th. Fourteen equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.
com, Biohaven currently has a consensus rating of “Buy” and a consensus target price of $62.77. Read Our Latest Research Report on BHVN Biohaven Company Profile ( Free Report ) Biohaven Ltd.
, together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. Further Reading Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Biohaven Ltd. ( NYSE:BHVN – Free Report ). Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.
com's FREE daily email newsletter ..
